|
|
|
|
Vol. 58, Issue 2, 279-287, August 2000
Laboratory of Pharmacology and Chemistry (C.-C.T, S.J.C., J.A.G.),
Laboratory of Experimental Pathology (J.F., R.M.), and Laboratory of
Pulmonary Pathobiology (D.C.Z.), National Institute of Environmental
Health Sciences, Research Triangle Park, North Carolina
ABSTRACT
We recently identified five different murine CYP2C cDNAs from a murine
cDNA library. When expressed in a bacterial cDNA expression system, all
five recombinant proteins metabolized arachidonic acid but
produced distinctly different profiles. In addition, some CYP2C mRNAs
were found in extrahepatic tissues, as well as in liver. Immunoblots
with an antibody raised against recombinant CYP2C38, which recognizes
all five murine CYP2Cs, demonstrated that among extrahepatic
tissues, colon and cecum contained the highest amount of CYP2Cs. The
highest concentration of CYP2Cs occurred in cecum and colon (cecum
proximal colon
distal colon), with lower levels in duodenum,
jejunum, and ileum. Immunohistochemical studies revealed that CYP2Cs
were localized principally in epithelial cells and autonomic ganglia in
gut and colon. Polymerase chain reaction amplification of
reverse-transcribed mRNA using murine CYP2C-specific primers followed
by cloning and sequencing identified CYP2C40 as the major CYP2C isoform
expressed in murine intestinal tract. Recombinant CYP2C40 metabolized
arachidonic acid in a regio- and stereospecific manner to
16(R)-HETE (hydroxyeicosatetraenoic acid) as the major
product. To our knowledge, CYP2C40 is the first enzyme known to produce
primarily 16-HETE. We conclude that CYP2C40 is one of the major
cytochrome P450 proteins in the mouse intestinal tract. In the light of
vasoactive and anti-neutrophilic effects of 16-HETE, we hypothesize
that CYP2C40 may play an important role in endogenous biological
functions in intestine.
This article has been cited by other articles:
![]() |
M. B. Dail, L. A. Shack, J. E. Chambers, and S. C. Burgess Global Liver Proteomics of Rats Exposed for 5 Days to Phenobarbital Identifies Changes Associated with Cancer and with CYP Metabolism Toxicol. Sci., December 1, 2008; 106(2): 556 - 569. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. C. DeLozier, C.-C. Tsao, S. J. Coulter, J. Foley, J. A. Bradbury, D. C. Zeldin, and J. A. Goldstein CYP2C44, a New Murine CYP2C That Metabolizes Arachidonic Acid to Unique Stereospecific Products J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 845 - 854. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Wang, Y. Zhao, J. A. Bradbury, J. P. Graves, J. Foley, J. A. Blaisdell, J. A. Goldstein, and D. C. Zeldin Cloning, Expression, and Characterization of Three New Mouse Cytochrome P450 Enzymes and Partial Characterization of Their Fatty Acid Oxidation Activities Mol. Pharmacol., May 1, 2004; 65(5): 1148 - 1158. [Abstract] [Full Text] |
||||
![]() |
L. S. Kaminsky and Q.-Y. Zhang THE SMALL INTESTINE AS A XENOBIOTIC-METABOLIZING ORGAN Drug Metab. Dispos., December 1, 2003; 31(12): 1520 - 1525. [Full Text] [PDF] |
||||
![]() |
Q.-Y. Zhang, D. Dunbar, and L. S. Kaminsky CHARACTERIZATION OF MOUSE SMALL INTESTINAL CYTOCHROME P450 EXPRESSION Drug Metab. Dispos., November 1, 2003; 31(11): 1346 - 1351. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Roman P-450 Metabolites of Arachidonic Acid in the Control of Cardiovascular Function Physiol Rev, January 1, 2002; 82(1): 131 - 185. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-C. Tsao, S. J. Coulter, A. Chien, G. Luo, N. P. Clayton, R. Maronpot, J. A. Goldstein, and D. C. Zeldin Identification and Localization of Five CYP2Cs in Murine Extrahepatic Tissues and Their Metabolism of Arachidonic Acid to Regio- and Stereoselective Products J. Pharmacol. Exp. Ther., October 1, 2001; 299(1): 39 - 47. [Abstract] [Full Text] [PDF] |
||||